Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Lyra Therapeutics, Inc. (LYRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/25/2023 |
SC 13G
| Samsara BioCapital, L.P. reports a 5.6% stake in Lyra Therapeutics, Inc. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
4/A
| Palasis Maria (President & CEO) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 150,000 options
@ $2.99, valued at
$448.5k
|
|
| 07/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/05/2023 |
4
| TOBIN JAMES R (Director) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 07/05/2023 |
4
| Smith W Bradford (Director) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 07/05/2023 |
4
| Poukalov Konstantin (Director) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 07/05/2023 |
4
| ALTMAN MICHAEL SETH (Director) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 07/05/2023 |
4
| MERRIFIELD C ANN (Director) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 07/05/2023 |
4
| ANDERSON EDWARD T (10% Owner) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 07/05/2023 |
4
| snyderman nancy lynn MD (Director) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 20,000 options
@ $4.11, valued at
$82.2k
|
|
| 06/28/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/12/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.9% stake in Lyra Therapeutics, Inc. |
| 06/09/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/09/2023 |
SC 13D/A
| NBVM GP, LLC reports a 12.2% stake in LYRA THERAPEUTICS, INC. |
| 05/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Form of Pre-Funded Warrant, together with a schedule of Pre-Funded Warrants, each, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Form of Purchase Warrant, together with a schedule of Purchase Warrants, each, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Securities Purchase Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Registration Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Lyra Therapeutics Announces $50.0 Million Private Placement May 26, 2023 WATERTOWN, Mass., May 26, 2023 — Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis, today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about May 31, 2023. Under the terms of the securities purchase agreement, Lyra has agreed to issue and sell approximately 17.7 million shares of the Company's common stock and pre-funded warrants to purc..." |
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- WATERTOWN, Mass., May 12, 2023 -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis , today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We've had a highly productive start to 2023, positioning us for anticipated key data readouts over the next 12 months,” said Maria Palasis, Ph.D., Pre..." |
|
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
4
| Bishop John E (Chief Technology Officer) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 220,000 options
@ $2.31, valued at
$508.2k
|
|
| 02/28/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/14/2023 |
SC 13G
| Nantahala Capital Management, LLC reports a 7% stake in Lyra Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PURA VIDA INVESTMENTS, LLC reports a 6.8% stake in Lyra Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
SC 13G/A
| Polaris Venture Partners V, L.P. reports a 4.5% stake in Lyra Therapeutics, Inc. |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Waksal Harlan (Executive Chair) has filed a Form 4 on Lyra Therapeutics, Inc.|
Txns:
| Granted 200,000 options
@ $2.85, valued at
$570k
|
|
|
|
|